CD79A and stage 5 chronic kidney disease: Differences between patients with early graft loss (<6 months) and remaining patients were age (55.7 ± 1.7 vs. 48.6 ± 0.5 years, p < 0.001), presence of DGF (50.9 vs. 23.8%, p < 0.001), positivity for IgA-aB2GP1 antibodies (65.5 vs. 36.8%, p < 0.001), and a higher proportion of patients with nephroangiosclerosis as cause of end-stage renal disease (ESRD) (20 vs. 7.2%, p = 0.001) (Table 3).